The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3

• Published in: Vaccine 2015-04, Vol.33 (15), p.1890-1896
• Main Authors: Churchyard, Gavin John, Snowden, Margaret Ann, Hokey, David, Dheenadhayalan, Veerabadran, McClain, J. Bruce, Douoguih, Macaya, Pau, Maria Grazia, Sadoff, Jerry, Landry, Bernard
• Format: Article
• Language: English
• Subjects: Adenovirus; Allergy and Immunology; Antigens; Blood pressure; Clinicaltrials.gov (NHREC no. NCT01017536); Cytokines; DOH-27-0809-2497; HIV; Human immunodeficiency virus; Human immunodeficiency virus 1; Immunization; Immunogenicity; Infections; Lymphocytes; Mycobacterium; Pharmacists; Public health; Safety; Tuberculosis; Urine; Vaccines
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2015.02.004

Abstract Background The safety and immunogenicity of a replication deficient adenovirus serotype 35 tuberculosis (TB) vaccine containing gene inserts for Antigens (Ag) 85A, Ag85B and TB10.4 (AERAS-402/AD35.TB-S) was evaluated in previously BCG vaccinated, HIV-infected South African adults with baseline CD4 counts >350 cells/mm3. Methods Subjects were randomized (1:1) to receive two doses of either intramuscular AERAS-402/AD35.TB-S or placebo at month 0 and at month 1. Participants were monitored for adverse events 28 days after each vaccination and for serious adverse events over 12 months. CD4+ and CD8+ T-cell and antibody responses to vaccine antigens were evaluated post first and second vaccination. Results 26 subjects were randomly assigned to receive AERAS-402/AD35.TB-S ( N = 13) or placebo ( N = 13). The mean age was 29.0 years, all were Black-African, 88.5% were female, 46.2% were QuantiFERON Test (QFT) positive at baseline, and the median CD4 count was 559.5 cells/mm3 , all similar by treatment group. All subjects received their first vaccination and 24 subjects received their second vaccination. Injection site reactions and some systemic reactions were reported more commonly in the AERAS-402/AD35.TB-S versus placebo recipients. AERAS-402/AD35.TB-S did not appear to influence CD4 counts and HIV-1 viral load over the course of study follow-up. AERAS-402/AD35.TB-S induced a mixed CD4+ T-cell and CD8+ T-cell responses to Ag85B. The CD4+ T-cell responses peaked to Ag85A and Ag85B 14 days after the second vaccination and had declined by Day 182. AERAS-402/AD35.TB-S predominantly induced CD4+ T-cells expressing three (IFN-γ, TNF, IL-2) or two (IL-2 and TNF) cytokines, two weeks after the last vaccination, which did not differ by baseline Quantiferon test status. AERAS-402/AD35.TB-S induced strong Ag85A and Ag85B specific antibody responses, particularly after the second vaccination. Conclusion AERAS-402/AD35.TB-S was well tolerated, safe and induced predominantly polyfunctional CD4+ and CD8+ T-cell responses to vaccine.